相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Celine Boutry et al.
CLINICAL INFECTIOUS DISEASES (2022)
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
Donald Hurley et al.
CLINICAL INFECTIOUS DISEASES (2021)
The disease burden of influenza beyond respiratory illness
Alejandro E. Macias et al.
VACCINE (2021)
Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
Desmond Curran et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2021)
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Lindsey R. Baden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies
Bart G. Pijls et al.
BMJ OPEN (2021)
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach
Aleena Banerji et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity
Zhuofan Li et al.
VACCINES (2021)
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
Hector S. Izurieta et al.
CLINICAL INFECTIOUS DISEASES (2021)
Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults >= 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons
Constantina Boikos et al.
CLINICAL INFECTIOUS DISEASES (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis
Adam Booth et al.
PLOS ONE (2021)
T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine
Anna Schmidt et al.
VIRUSES-BASEL (2021)
Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality
M. Flook et al.
BMC INFECTIOUS DISEASES (2021)
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review
Eleni Korompoki et al.
JOURNAL OF INFECTION (2021)
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Eric J. Haas et al.
LANCET (2021)
Post-acute COVID-19 syndrome
Ani Nalbandian et al.
NATURE MEDICINE (2021)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Jerald Sadoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
Ian McDonald et al.
NPJ VACCINES (2021)
Squalene-Based Influenza Vaccine Adjuvants and Their Impact on the Hemagglutinin-Specific B Cell Response
Phuong Nguyen-Contant et al.
PATHOGENS (2021)
Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021
Thomas Harderi et al.
EUROSURVEILLANCE (2021)
Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021
Clara Mazagatos et al.
EUROSURVEILLANCE (2021)
THE CASE IS GROWING FOR MIX-AND-MATCH COVID VACCINES
Dyani Lewis
NATURE (2021)
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Dami A. Collier et al.
NATURE (2021)
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Jamie Lopez Bernal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Jay Montgomery et al.
JAMA CARDIOLOGY (2021)
Vaccines and Senior Travellers
Fiona Ecarnot et al.
FRONTIERS IN AGING (2021)
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
Peter Vink et al.
CLINICAL INFECTIOUS DISEASES (2020)
Is a Universal Influenza Virus Vaccine Possible?
Raffael Nachbagauer et al.
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Aging and influenza vaccine-induced immunity
Haley L. Dugan et al.
CELLULAR IMMUNOLOGY (2020)
Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults
Brandon Essink et al.
VACCINE (2020)
Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study
Robertus van Aalst et al.
VACCINE (2020)
Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial
Leilani Sanchez et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial
Benjamin J. Cowling et al.
CLINICAL INFECTIOUS DISEASES (2020)
Next-generation influenza vaccines: opportunities and challenges
Chih-Jen Wei et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults
Cheryl A. Keech et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2020)
The immune response to influenza in older humans: beyond immune senescence
Janet E. McElhaney et al.
IMMUNITY & AGEING (2020)
Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection
Malihe Masomian et al.
VACCINES (2020)
Norovirus Vaccine: Priorities for Future Research and Development
Susanna Esposito et al.
FRONTIERS IN IMMUNOLOGY (2020)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Maheshi N. Ramasamy et al.
LANCET (2020)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Fernando P. Polack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses
James P. Phipps et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine
Adriana Weinberg et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis
Nirma Khatri Vadlamudi et al.
VACCINE (2019)
Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review
Marie-Aleth Lacaille-Dubois
PHYTOMEDICINE (2019)
Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017
Angel Vila-Corcoles et al.
EUROSURVEILLANCE (2019)
Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses
Michael A. Carlock et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
Alemnew F. Dagnew et al.
LANCET INFECTIOUS DISEASES (2019)
Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up
C. Raina MacIntyre et al.
VACCINE (2019)
Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial
Lee-Jah Chang et al.
VACCINE (2019)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Development of a Universal Influenza Vaccine
Leonardo D. Estrada et al.
JOURNAL OF IMMUNOLOGY (2019)
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
Helen L. Stacey et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens
Theano Lagousi et al.
VACCINES (2019)
Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
Fawziah Marra et al.
AGING AND DISEASE (2019)
Adjuvant strategies to improve vaccination of the elderly population
Birgit Weinberger
CURRENT OPINION IN PHARMACOLOGY (2018)
Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage
Shahzma Merani et al.
EXPERIMENTAL GERONTOLOGY (2018)
Protection against Tetanus and Diphtheria in Europe: The impact of age, gender and country of origin based on data from the MARK-AGE Study
Birgit Weinberger et al.
EXPERIMENTAL GERONTOLOGY (2018)
Escherichia coli and Staphylococcus aureus: leading bacterial pathogens of healthcare associated infections and bacteremia in older-age populations
Jan T. Poolman et al.
EXPERT REVIEW OF VACCINES (2018)
Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis
Jason K. H. Lee et al.
EXPERT REVIEW OF VACCINES (2018)
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
Anthony L. Cunningham et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial
Drew J. Winston et al.
LANCET (2018)
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Natalie I. Mazur et al.
LANCET INFECTIOUS DISEASES (2018)
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Giuseppe Del Giudice et al.
SEMINARS IN IMMUNOLOGY (2018)
Adjuvanted influenza vaccines
John S. Tregoning et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
Brian J. Ward et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
Tino F. Schwarz et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults
Birgit Weinberger et al.
FRONTIERS IN IMMUNOLOGY (2018)
Th1 memory differentiates recombinant from live herpes zoster vaccines
Myron J. Levin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination
Joseph J. Campo et al.
ELIFE (2018)
Vaccines for preventing influenza in healthy adults
Vittorio Demicheli et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Adult vaccination against tetanus and diphtheria: the European perspective
B. Weinberger
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Arnaud M. Didierlaurent et al.
EXPERT REVIEW OF VACCINES (2017)
Pneumococcal whole-cell and protein-based vaccines: changing the paradigm
Michael E. Pichichero
EXPERT REVIEW OF VACCINES (2017)
Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults
Janet E. McElhaney et al.
VACCINE (2017)
Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis
Krista Wilkinson et al.
VACCINE (2017)
IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine
Ivana B. Campos et al.
VACCINE (2017)
Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis
Alexander Domnich et al.
VACCINE (2017)
Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21
Iain Welsby et al.
FRONTIERS IN IMMUNOLOGY (2017)
Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
Carla L. Black et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2017)
Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
Gerhard Falkenhorst et al.
PLOS ONE (2017)
Pneumococcal Capsular Polysaccharide Immunity in the Elderly
Hugh Adler et al.
CLINICAL AND VACCINE IMMUNOLOGY (2017)
Next generation protein based Streptococcus pneumoniae vaccines
Michael E. Pichichero et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type
Richard K. Zimmerman et al.
CLINICAL INFECTIOUS DISEASES (2016)
Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective
Lindsay Kim et al.
CLINICAL MICROBIOLOGY REVIEWS (2016)
I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
E. Kissling et al.
EUROSURVEILLANCE (2016)
The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis
Eili Y. Klein et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2016)
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
A. L. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations
Daniela Frasca et al.
VACCINE (2016)
The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis (vol 34, pg 1540, 2016)
Hannah Kraicer-Melamed et al.
VACCINE (2016)
Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials
Wen-qi Diao et al.
VACCINE (2016)
Booster vaccination against tetanus and diphtheria: insufficient protection against diphtheria in young and elderly adults
Marco Grasse et al.
IMMUNITY & AGEING (2016)
Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk - A Systematic Review and Meta-Analysis
Julia Schiffner-Rohe et al.
PLOS ONE (2016)
Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes
Theone C. Kon et al.
PLOS ONE (2016)
Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01
Sophie Detienne et al.
SCIENTIFIC REPORTS (2016)
Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom
Douglas M. Fleming et al.
BMC INFECTIOUS DISEASES (2015)
Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination
Giuseppe Lofano et al.
JOURNAL OF IMMUNOLOGY (2015)
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Himal Lal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults
Steven Black
VACCINE (2015)
H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps
Hang Xie et al.
SCIENTIFIC REPORTS (2015)
Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review
Barbara Camilloni et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Long-term Persistence of Zoster Vaccine Efficacy
Vicki A. Morrison et al.
CLINICAL INFECTIOUS DISEASES (2015)
Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
Elchonon M. Berkowitz et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Functional decline and herpes zoster in older people: an interplay of multiple factors
Herpes Zoster
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2015)
Pneumococcal infection in adults: burden of disease
J. J. C. Drijkoningen et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Postherpetic Neuralgia
Robert W. Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
Carlos A. DiazGranados et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
C. Raina MacIntyre et al.
PLOS ONE (2014)
Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study
Roman Chlibek et al.
VACCINE (2014)
Systematic review of incidence and complications of herpes zoster: towards a global perspective
Kosuke Kawai et al.
BMJ OPEN (2014)
Vaccine Effectiveness Against Laboratory-Confirmed Influenza Hospitalizations Among Elderly Adults During the 2010-2011 Season
Jeffrey C. Kwong et al.
CLINICAL INFECTIOUS DISEASES (2013)
Pneumococcal vaccine and opsonic pneumococcal antibody
Joon Young Song et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2013)
Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults ≥50 Years of Age
Roman Chlibek et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
Janet E. McElhaney et al.
LANCET INFECTIOUS DISEASES (2013)
Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons
Birgit Weinberger et al.
PLOS ONE (2013)
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial
William H. Yang et al.
VACCINE (2013)
Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review
Ellen Rafferty et al.
VACCINE (2013)
Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease
Tomohiro Oishi et al.
VACCINE (2013)
Cross-protection against drifted influenza viruses Options offered by adjuvanted and intradermal vaccines
Andrea Orsi et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Kenneth E. Schmader et al.
CLINICAL INFECTIOUS DISEASES (2012)
A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults
Isabel Leroux-Roels et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
Benjamin Petsch et al.
NATURE BIOTECHNOLOGY (2012)
Age Affects Quantity but Not Quality of Antibody Responses after Vaccination with an Inactivated Flavivirus Vaccine against Tick-Borne Encephalitis
Karin Stiasny et al.
PLOS ONE (2012)
The importance of pertussis in older adults: A growing case for reviewing vaccination strategy in the elderly
Iman Ridda et al.
VACCINE (2012)
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose
Scott A. Halperin et al.
VACCINE (2012)
Age-related changes in human peripheral blood IGH repertoire following vaccination
Yu-Chang Bryan Wu et al.
FRONTIERS IN IMMUNOLOGY (2012)
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2011)
Older Adults Have a Low Capacity To Opsonize Pneumococci Due to Low IgM Antibody Response to Pneumococcal Vaccinations
Saeyoung Park et al.
INFECTION AND IMMUNITY (2011)
Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults
Xu Yao et al.
VACCINE (2011)
Options for Inactivation, Adjuvant, and Route of Topical Administration of a Killed, Unencapsulated Pneumococcal Whole-Cell Vaccine
Ying-Jie Lu et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
The impact of varicella zoster virus: Chronic pain
Wim Opstelten et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Toll-Like Receptor Agonists Allow Generation of Long-Lasting Antipneumococcal Humoral Immunity in Response to a Plain Polysaccharidic Vaccine
Morgan Taillardet et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Tamara Pilishvili et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50-90 years
Birgit Weinberger et al.
VACCINE (2010)
Clinical and immunologic predictors of influenza illness among vaccinated older adults
Zainab Shahid et al.
VACCINE (2010)
The seroepidemiology of Bordetella pertussis in Israel-Estimate of incidence of infection
Pamela Rendi-Wagner et al.
VACCINE (2010)
GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis
Ying-Jie Lu et al.
VACCINE (2010)
Immune Response in Infants to the Heptavalent Pneumococcal Conjugate Vaccine against Vaccine-Related Serotypes 6A and 19A
Hyunju Lee et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55-70 Years of Age
Karen M. Miernyk et al.
CLINICAL INFECTIOUS DISEASES (2009)
Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations
Odile Launay et al.
HUMAN VACCINES (2009)
Efficacy of Inactivated Split-Virus Influenza Vaccine against Culture-Confirmed Influenza in Healthy Adults: A Prospective, Randomized, Placebo-Controlled Trial
Jiri Beran et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004-2005 Season to the 2006-2007 Season
Edward A. Belongia et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
IC31®, a Two-Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
T. A. Olafsdottir et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2009)
Immunological responses to pneumococcal vaccine in frail older people
I. Ridda et al.
VACCINE (2009)
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults:: Conjugate vaccine elicits improved antibacterial immune responses and immunological memory
Andres de Roux et al.
CLINICAL INFECTIOUS DISEASES (2008)
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine
M. J. Levin et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
Filippo Ansaldi et al.
VACCINE (2008)
Booster vaccination in the elderly:: Their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers
Maria Kaml et al.
VACCINE (2006)
CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells
Dominic F. Kelly et al.
BLOOD (2006)
Critical differences between pneumococcal polysaccharide enzyme-linked Immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera
I Henckaerts et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Antibody response to influenza vaccination in the elderly: A quantitative review
K Goodwin et al.
VACCINE (2006)
The effect of aging on cognate function and development of immune memory
L Haynes
CURRENT OPINION IN IMMUNOLOGY (2005)
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
MN Oxman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults
P Van Damme et al.
VACCINE (2004)
Immunomodulating effect of influenza vaccination in the elderly differing in health status
J Mysliwska et al.
EXPERIMENTAL GERONTOLOGY (2004)
CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly
L Haynes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Immunogenicity of combined hepatitis A and B vaccine in elderly persons
B Wolters et al.
VACCINE (2003)
The effect of age on immunologic response to recombinant hepatitis B vaccine: A meta-analysis
DN Fisman et al.
CLINICAL INFECTIOUS DISEASES (2002)
Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine healthy toddlers
T Wuorimaa et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2001)
Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine
P Richmond et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
分享论文
